Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hinde El Otmani

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Current Opinion in Hematology|May 9, 2024
Improving our understanding on the clinical role of plasmin-mediated von Willebrand factor degradationHinde El Otmani, Karen Vanhoorelbeke, Claudia Tersteeg
Journal of Thrombosis and Haemostasis : JTH|June 19, 2024
Factor XII contact activation can be prevented by targeting 2 unique patches in its epidermal growth factor-like 1 domain with a nanobodyRowan Frunt, Hinde El Otmani, Simone Smits, et al.
Thrombosis and Haemostasis|September 27, 2022
Factor XII Explored with AlphaFold - Opportunities for Selective Drug DevelopmentRowan Frunt, Hinde El Otmani, Bubacarr Gibril Kaira, et al.
Research and Practice in Thrombosis and Haemostasis|October 2, 2025
Plasmin-mediated proteolysis of von Willebrand factor in patients with acute and chronic liver diseaseHinde El Otmani, Marilena Stamouli, Jelle Adelmeijer, et al.
Blood|January 25, 2024
Plasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosisHinde El Otmani, Rowan Frunt, Simone Smits, et al.
Journal of Thrombosis and Haemostasis : JTH|October 15, 2021
Targeted SERPIN (TaSER): A dual-action antithrombotic agent that targets platelets for SERPIN deliveryWariya Sanrattana, Simone Smits, Arjan D Barendrecht, et al.
Blood|November 9, 2021
Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosisSteven de Maat, Chantal C Clark, Arjan D Barendrecht, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Current Opinion in Hematology|May 9, 2024
Improving our understanding on the clinical role of plasmin-mediated von Willebrand factor degradationHinde El Otmani, Karen Vanhoorelbeke, Claudia Tersteeg
Journal of Thrombosis and Haemostasis : JTH|June 19, 2024
Factor XII contact activation can be prevented by targeting 2 unique patches in its epidermal growth factor-like 1 domain with a nanobodyRowan Frunt, Hinde El Otmani, Simone Smits, et al.
Thrombosis and Haemostasis|September 27, 2022
Factor XII Explored with AlphaFold - Opportunities for Selective Drug DevelopmentRowan Frunt, Hinde El Otmani, Bubacarr Gibril Kaira, et al.
Research and Practice in Thrombosis and Haemostasis|October 2, 2025
Plasmin-mediated proteolysis of von Willebrand factor in patients with acute and chronic liver diseaseHinde El Otmani, Marilena Stamouli, Jelle Adelmeijer, et al.
Blood|January 25, 2024
Plasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosisHinde El Otmani, Rowan Frunt, Simone Smits, et al.
Journal of Thrombosis and Haemostasis : JTH|October 15, 2021
Targeted SERPIN (TaSER): A dual-action antithrombotic agent that targets platelets for SERPIN deliveryWariya Sanrattana, Simone Smits, Arjan D Barendrecht, et al.
Blood|November 9, 2021
Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosisSteven de Maat, Chantal C Clark, Arjan D Barendrecht, et al.
Pageof 1